drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor (CAR) T-cell therapy targeting glypican-3 (GPC3) on hepatocellular carcinoma; patient T cells are engineered to express an anti-GPC3 CAR that, upon antigen engagement, activates T cells and induces perforin/granzyme-mediated cytotoxicity against GPC3-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-GPC3 chimeric antigen receptor; binding to GPC3 on hepatocellular carcinoma cells triggers CAR signaling, T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive tumor cells.
drug_name
CT011 CAR-GPC3 T Cells
nct_id_drug_ref
NCT06560827